Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
DAREON-9
DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
- NCT05990738 ↗
- Active, not recruiting
- Boehringer Ingelheim
- Focused
We haven't built an HCP commentary report on DAREON-9 (BI 764532 and topotecan in Small Cell Lung Carcinoma (SCLC)) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on DAREON-9 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 2 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- DAREON™-9: A Phase Ib Open-label Dose Escalation and Dose Confirmation Safety Study of Intravenous BI 764532 in Combination With a Single Agent Chemotherapy for the Treatment of Patients With Relapsed/Refractory Small Cell Lung Cancer After Platinum-based Chemotherapy
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Small Cell Lung Carcinoma (SCLC)
- Interventions
- BI 764532; Topotecan; Single agent chemotherapy
- Arms
- Part A: BI 764532 low dose + topotecan/single agent chemotherapy · Experimental
- Part A: BI 764532 medium dose + topotecan/single agent chemotherapy · Experimental
- Part A: BI 764532 high dose + topotecan/single agent chemotherapy · Experimental
- Part B: BI 764532 + topotecan · Experimental
- Enrollment
- 69
- Primary outcomes
- Part A: Occurrence of dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
- Part B: Occurrence of DLTs during the on-treatment period
- Part B: Occurrence of AEs during the on-treatment period
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 14, 2024
- Primary completion
- Mar 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05990738 · updated Sep 15, 2026